Therapeutic targets in triple negative breast cancer - where are we now?

Area of Science:

• Oncology
• Genetics
• Cancer Research

Background:

• Triple negative breast cancer (TNBC) is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2/EGFR2 expression.
• TNBC exhibits aggressive clinical behavior, higher recurrence rates, and a predilection for brain and lung metastasis.
• Prevalence varies significantly across ethnicities, with higher rates observed in individuals of African descent.

Purpose of the Study:

• To review recent patents related to triple negative breast cancer.
• To explore the intricate relationship between TNBC, basal-like breast cancer, and BRCA1-linked breast carcinomas.
• To discuss potential treatment modalities and innovations for TNBC, focusing on predictive and prognostic values.

Main Methods:

• Literature review of recent patents and scientific publications.
• Analysis of the molecular and clinical characteristics of triple negative breast cancer.
• Synthesis of information on therapeutic strategies and diagnostic advancements.

Main Results:

• Identified a growing body of research and patent activity surrounding TNBC.
• Highlighted the strong association between TNBC, basal-like subtypes, and BRCA1 mutations.
• Discussed emerging treatment approaches targeting specific pathways and biomarkers.

Conclusions:

• TNBC remains a challenging subtype of breast cancer due to its aggressive nature and limited targeted therapies.
• Understanding the links between TNBC, basal-like cancers, and BRCA1 is crucial for developing effective treatments.
• Ongoing research and patent innovations offer promise for improved predictive, prognostic, and therapeutic strategies for TNBC.